TY - JOUR
T1 - IL-2 regulation of soluble IL-2 receptor levels following thermal injury
AU - Teodorczyk-Injeyan, J. A.
AU - Sparkes, B. G.
AU - Lalani, S.
AU - Peters, W. J.
AU - Mills, G. B.
PY - 1992
Y1 - 1992
N2 - In the immunosuppressed burn patient serum levels of both IL-2 and a soluble form of IL-2 receptor alpha (sIL-2Rα) are significantly elevated. Strikingly, the production of these markers by the in vitro activated patients' cells is decreased. This study examines the role of IL-2 in the decreased production of the sIL-2Rα in vitro in patients with major burns (n = 18, 30 to >70% total body surface area). Peripheral blood mononuclear cell (PBMC) cultures from patients with highly elevated serum sIL-2Rα, and from healthy controls (n = 12) were activated with concanavalin A (Con A) at initiation. In patients' cultures mitogen-induced increments of sIL-2Rα levels were significantly lower. There was a significant negative correlation (r = -0.64, P < 0.001) between a high serum sIL-2Rα level and a decreased lectin-induced sIL-2Rα release in vitro. Low levels of sIL-2Rα in patients' samples were not normalized by increasing the number of T lymphocytes. Also exogenous rIL-1 was without effect, whereas rIL-3 increased sIL-2Rα release in some cultures. However, sIL-2Rα levels were significantly increased in patients' cultures by (i) addition of exogenous IL-2; (ii) removal of adherent cells; (iii) addition of cyclooxygenase inhibitor, indomethacin; (iv) bypassing cell surface activation by the combination of the calcium ionophore A23187 and the phorbol ester 12-o-tetradecanoyl acetate. The cyclic AMP-elevating drug, forskolin, abrogated the ability of exogenous IL-2 to increase sIL-2Rα production. Thus, in the burn patient, the reduced in vitro sIL-2Rα release appears to relate to abnormalities in IL-2 production and action mediated through its functional surface receptor. Elevated levels of sIL-2Rα in vivo may, therefore, reflect systemic activation of T lymphocytes in response to biologically active IL-2.
AB - In the immunosuppressed burn patient serum levels of both IL-2 and a soluble form of IL-2 receptor alpha (sIL-2Rα) are significantly elevated. Strikingly, the production of these markers by the in vitro activated patients' cells is decreased. This study examines the role of IL-2 in the decreased production of the sIL-2Rα in vitro in patients with major burns (n = 18, 30 to >70% total body surface area). Peripheral blood mononuclear cell (PBMC) cultures from patients with highly elevated serum sIL-2Rα, and from healthy controls (n = 12) were activated with concanavalin A (Con A) at initiation. In patients' cultures mitogen-induced increments of sIL-2Rα levels were significantly lower. There was a significant negative correlation (r = -0.64, P < 0.001) between a high serum sIL-2Rα level and a decreased lectin-induced sIL-2Rα release in vitro. Low levels of sIL-2Rα in patients' samples were not normalized by increasing the number of T lymphocytes. Also exogenous rIL-1 was without effect, whereas rIL-3 increased sIL-2Rα release in some cultures. However, sIL-2Rα levels were significantly increased in patients' cultures by (i) addition of exogenous IL-2; (ii) removal of adherent cells; (iii) addition of cyclooxygenase inhibitor, indomethacin; (iv) bypassing cell surface activation by the combination of the calcium ionophore A23187 and the phorbol ester 12-o-tetradecanoyl acetate. The cyclic AMP-elevating drug, forskolin, abrogated the ability of exogenous IL-2 to increase sIL-2Rα production. Thus, in the burn patient, the reduced in vitro sIL-2Rα release appears to relate to abnormalities in IL-2 production and action mediated through its functional surface receptor. Elevated levels of sIL-2Rα in vivo may, therefore, reflect systemic activation of T lymphocytes in response to biologically active IL-2.
KW - Burn immunosuppression
KW - IL-2
KW - IL-2 receptor
KW - T cell activation
UR - http://www.scopus.com/inward/record.url?scp=0026661172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026661172&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2249.1992.tb05828.x
DO - 10.1111/j.1365-2249.1992.tb05828.x
M3 - Article
C2 - 1382903
AN - SCOPUS:0026661172
SN - 0009-9104
VL - 90
SP - 36
EP - 42
JO - Clinical and Experimental Immunology
JF - Clinical and Experimental Immunology
IS - 1
ER -